Should you consider NASDAQ:AMPH for growth investing?

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, which makes it worth to investigate a bit more.

Looking into the canslim metrics of AMPHASTAR PHARMACEUTICALS IN

• The EPS of AMPHASTAR PHARMACEUTICALS IN has exhibited growth from one quarter to another (Q2Q), with a 203.0% increase. This underscores the company's ability to generate higher earnings and improve its financial standing.
• The recent q2q revenue growth of 50.37% of AMPHASTAR PHARMACEUTICALS IN showcases the company's ability to generate increasing revenue in a short period, reflecting its positive growth trajectory.
• The 3-year EPS growth of AMPHASTAR PHARMACEUTICALS IN (77.88%) highlights the company's ability to consistently improve its earnings performance and suggests a positive outlook for future profitability.
• AMPHASTAR PHARMACEUTICALS IN has achieved an impressive Return on Equity (ROE) of 22.72%, showcasing its ability to generate favorable returns for shareholders.
• The Relative Strength (RS) of AMPHASTAR PHARMACEUTICALS IN has been consistently solid, with a current 96.23 rating. This highlights the stock's ability to exhibit sustained price strength and signifies its competitive advantage. AMPHASTAR PHARMACEUTICALS IN exhibits strong prospects for further price appreciation.
• With a Debt-to-Equity ratio at 1.07, AMPHASTAR PHARMACEUTICALS IN showcases its prudent financial management. The company's balanced approach between debt and equity reflects its commitment to maintaining a stable capital structure.
• AMPHASTAR PHARMACEUTICALS IN demonstrates a balanced ownership structure, with institutional shareholders at 66.59%. This indicates a diverse investor base, which can contribute to price stability and potential future growth.

Analyzing the Technical Aspects

Every day, ChartMill assigns a Technical Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various technical indicators and properties.

We assign a technical rating of 9 out of 10 to AMPH. In the last year, AMPH was one of the better performers in the market. There are positive signs in the very recent evolution, but the medium term picture is slightly mixed.

• The long and short term trends are both positive. This is looking good!
• When comparing the yearly performance of all stocks, we notice that AMPH is one of the better performing stocks in the market, outperforming 96% of all stocks. We also observe that the gains produced by AMPH over the past year are nicely spread over this period.
• AMPH is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 93% of 203 stocks in the same industry.
• AMPH is currently trading in the upper part of its 52 week range. The S&P500 Index however is currently trading near a new high, so AMPH is lagging the market slightly.
• In the last month AMPH has a been trading in the 54.06 - 62.72 range, which is quite wide. It is currently trading near the high of this range.

Our latest full technical report of AMPH contains the most current technical analsysis.

Zooming in on the fundamentals.

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

Overall AMPH gets a fundamental rating of 7 out of 10. We evaluated AMPH against 203 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: AMPH is growing strongly while it also seems undervalued. This makes AMPH very considerable for value and growth investing!

Our latest full fundamental report of AMPH contains the most current fundamental analsysis.

Our CANSLIM screen will find you more ideas suited for growth investing.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.